IL4、MGMT和AKT1胚系变异与前列腺癌特异性死亡率相关:12,082例前列腺癌分析
该研究在7个前列腺癌队列(12,082例患者,1,544例前列腺癌死亡)中对22个既往报道与前列腺癌特异性死亡率(PCSM)相关的遗传变异进行基因分型,采用Cox比例风险模型计算风险比,并进行meta分析。经过临床病理因素调整后,meta分析证实MGMT rs2308327(HR 0.90;p=3.5×10^-2)和IL4 rs2070874(HR 1.22;p=1.1×10^-3)与PCSM风险相关;在局限或区域期患者中,AKT1 rs2494750(HR 0.81;p=3.6×10^-2)亦与PCSM风险相关。
要点
- MGMT rs2308327与PCSM风险降低相关(HR 0.90;p=3.5×10^-2)。
- IL4 rs2070874与PCSM风险升高相关(HR 1.22;p=1.1×10^-3)。
- 局限或区域期患者中AKT1 rs2494750与PCSM风险降低相关(HR 0.81;p=3.6×10^-2)。
核心结论
- 该meta分析证实三个遗传变异与前列腺癌特异性死亡风险相关,进一步表明遗传背景在前列腺癌特异性生存中起作用。
- 这些变异单独不足以作为预后生物标志物,但结果可能为调节肿瘤侵袭性的生物学通路提供线索。
研究设计与样本
- 在7个前列腺癌队列(12,082例患者;1,544例前列腺癌死亡)中对22个既往识别的PCSM相关遗传变异进行基因分型。
- 每个队列使用Cox比例风险模型计算PCSM风险的风险比(HR)和95%置信区间(CI),数据通过meta分析方法合并。
主要发现
- 15个SNP在7个队列中至少一个队列与PCSM相关。
- meta分析中,经临床病理因素调整后,MGMT rs2308327(HR 0.90;p=3.5×10^-2)和IL4 rs2070874(HR 1.22;p=1.1×10^-3)与PCSM风险相关。
- 在局限或区域期患者分析中,AKT1 rs2494750(HR 0.81;p=3.6×10^-2)与PCSM风险相关。
关键数值与推荐
- MGMT rs2308327:HR 0.90;p=3.5×10^-2(经临床病理因素调整)。
- IL4 rs2070874:HR 1.22;p=1.1×10^-3(经临床病理因素调整)。
- AKT1 rs2494750:HR 0.81;p=3.6×10^-2(局限或区域期患者)。
临床怎么用
- 这些变异单独不足以作为预后生物标志物。
- 结果可能为调节肿瘤侵袭性的生物学通路提供线索。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer (PCa) is a leading cause of mortality and genetic factors can influence tumour aggressiveness. Several germline variants have been associated with PCa-specific mortality (PCSM), but further replication evidence is needed. METHODS: Twenty-two previously identified PCSM-associated genetic variants were genotyped in seven PCa cohorts (12,082 patients; 1544 PCa deaths). For each cohort, Cox proportional hazards models were used to calculate hazard ratios and 95% confidence intervals for risk of PCSM associated with each variant. Data were then combined using a meta-analysis approach. RESULTS: Fifteen SNPs were associated with PCSM in at least one of the seven cohorts. In the meta-analysis, after adjustment for clinicopathological factors, variants in the MGMT (rs2308327; HR 0.90; p-value = 3.5 × 10-2) and IL4 (rs2070874; HR 1.22; p-value = 1.1 × 10-3) genes were confirmed to be associated with risk of PCSM. In analyses limited to men diagnosed with local or regional stage disease, a variant in AKT1, rs2494750, was also confirmed to be associated with PCSM risk (HR 0.81; p-value = 3.6 × 10-2). CONCLUSIONS: This meta-analysis confirms the association of three genetic variants with risk of PCSM, providing further evidence that genetic background plays a role in PCa-specific survival. While these variants alone are not sufficient as prognostic biomarkers, these results may provide insights into the biological pathways modulating tumour aggressiveness.
引用
- FitzGerald LM, Zhao S, Leonardson A, et al. Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer Prostatic Dis. 2018. PMID: 29298992. doi:10.1038/s41391-017-0029-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。